Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.39 |
| ▸ | PDE1A | P54750 | 3/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CCR4 | P51679 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13834302 | 0.93 | JAK2 (0.47) | JAK2LRRK2PDE1BPDE1APDE1C | |
| SCHEMBL13834301 | 0.93 | JAK2 (0.47) | JAK2LRRK2PDE1BPDE1APDE1C | |
| SCHEMBL416412 | 0.92 | JAK2 (0.48) | JAK2AOC3NR1H4ALDH1A1L3MBTL1 | |
| SCHEMBL416411 | 0.92 | JAK2 (0.48) | JAK2AOC3NR1H4ALDH1A1L3MBTL1 | |
| SCHEMBL19730493 | 0.86 | JAK2 (0.47) | JAK2LRRK2PDE1BPDE1APDE1C | |
| SCHEMBL19730136 | 0.84 | JAK2 (0.39) | JAK2ALDH1A1L3MBTL1CCR4POLB | |
| SCHEMBL31500887 | 0.84 | JAK2 (0.39) | JAK2ALDH1A1L3MBTL1CCR4POLB | |
| SCHEMBL3770096 | 0.83 | JAK2 (0.47) | JAK2AOC3ALDH1A1POLB | |
| SCHEMBL3770100 | 0.83 | JAK2 (0.47) | JAK2AOC3ALDH1A1POLB | |
| SCHEMBL883468 | 0.82 | JAK2 (0.48) | JAK2LRRK2PDE1BPDE1APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012038743-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295883-A1 | COMPOUNDS | ABCC5, PRNP, PC | JAK2 2080/4885LRRK2 1512/4885PDE1B 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.